FASANO, MASSIMO
 Distribuzione geografica
Continente #
EU - Europa 2.860
NA - Nord America 1.969
AS - Asia 1.495
Continente sconosciuto - Info sul continente non disponibili 21
SA - Sud America 11
OC - Oceania 4
AF - Africa 2
Totale 6.362
Nazione #
US - Stati Uniti d'America 1.963
IE - Irlanda 1.091
CN - Cina 956
UA - Ucraina 709
SE - Svezia 479
FR - Francia 203
IN - India 202
TR - Turchia 178
FI - Finlandia 163
VN - Vietnam 118
IT - Italia 75
GB - Regno Unito 54
DE - Germania 43
EU - Europa 21
SG - Singapore 17
BE - Belgio 14
AT - Austria 9
SY - Repubblica araba siriana 7
UY - Uruguay 7
PK - Pakistan 6
RU - Federazione Russa 6
CA - Canada 4
BG - Bulgaria 3
CH - Svizzera 3
ES - Italia 3
AR - Argentina 2
AU - Australia 2
CZ - Repubblica Ceca 2
HK - Hong Kong 2
IR - Iran 2
KR - Corea 2
MX - Messico 2
NL - Olanda 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
CL - Cile 1
GH - Ghana 1
IQ - Iraq 1
ML - Mali 1
MY - Malesia 1
PE - Perù 1
RS - Serbia 1
TH - Thailandia 1
Totale 6.362
Città #
Dublin 1.089
Jacksonville 505
Dearborn 317
Nyköping 298
Nanjing 281
Chandler 249
Wilmington 137
Dong Ket 117
Nanchang 102
Princeton 102
Beijing 101
San Mateo 79
Helsinki 69
Shenyang 60
Hebei 52
Kunming 51
Tianjin 44
Ashburn 39
Ann Arbor 35
Changsha 34
Jiaxing 34
Ningbo 29
Jinan 26
Stevenage 24
Des Moines 23
Zhengzhou 21
Hilden 19
Hangzhou 17
Guangzhou 15
Lanzhou 15
Taizhou 13
Brussels 12
London 12
Redwood City 12
New York 11
Pune 9
Vienna 9
Woodbridge 9
Ankara 8
Chengdu 8
Foggia 8
Shanghai 8
Montevideo 7
Orange 7
San Jose 7
Hefei 6
Norwalk 6
Bari 5
Boardman 5
Changchun 5
Hanover 5
Augusta 4
Chicago 4
Fairfield 4
Leawood 4
Zhangzhou 4
Borås 3
Fuzhou 3
Gurgaon 3
Istanbul 3
Jinhua 3
Rockville 3
Saint Petersburg 3
Brno 2
Central 2
Elche 2
Gunzenhausen 2
Kraainem 2
Modena 2
Oxford 2
Palo del Colle 2
Paris 2
Pennington 2
Perm 2
Pesaro 2
Priverno 2
Redmond 2
Rome 2
Singapore 2
Acquaviva Delle Fonti 1
Auckland 1
Balıkesir 1
Baotou 1
Bethesda 1
Brindisi 1
Brooklyn 1
Cedar Knolls 1
Chongqing 1
Christchurch 1
Dammam 1
Edinburgh 1
Edmonton 1
Federal 1
Florence 1
Gaziantep 1
Geneva 1
Gijón 1
Greenwich 1
Haikou 1
Hanoi 1
Totale 4.250
Nome #
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 155
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 128
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 114
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 109
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 93
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 92
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 89
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 89
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 88
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 87
Flares during long-term entecavir therapy in chronic hepatitis B 84
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 83
Tenofovir suppressed viral suppression in most field practice, treatment-naive patients with CHB followed for 3 years in a multicenter European study 78
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 78
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 77
Efficacia e tollerabilità della monoterapia con Entecavir (ETV) in pazienti con epatite cronica B 74
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 74
THE ITALIAN ENTAS COHORT STUDY: ENTECAVIR EFFECTIVENESS IN NAïVE AND TREATMENT EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B 73
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 73
Nuove strategie di trattamento 72
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 72
Current Concepts on Management of Chronic Hepatitis BPractical Management of Chronic Viral Hepatitis 71
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 71
Cost-effectiveness of Tenofovir in the treatment of patients with chronic hepatitis B: data from literature 71
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 70
Resistance profile of entecavir in patients with chronic hepatitis B 69
Detection of in vivo hepatitis B virus surface antigen mutations-a comparison of four routine screening assays 69
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C 68
A proposito di epatite B. News da EASL 2008. 68
Definizione delle resistenze e metodiche di laboratorio 68
Come trattare il paziente con non risposta o risposta virologica parziale 68
Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. 68
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 67
Risposta virologica e resistenza ad Adefovir dipivoxil (ADV) in pazienti con Epatite Cronica B resistente alla Lamivudina (LAM) 67
Risposta alla terapia con Adefovir Dipivoxil (ADV) in pazienti con Epatite Cronica B, resistenti alla Lamivudina 67
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 67
Long-term response to lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B: to change or not to change? 66
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 66
Chronic hepatitis B: Advances in treatment. 66
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 65
Effectiveness of entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 65
Epatite acuta C in un’ampia coorte di pazienti: fattori di rischio ed evoluzione 65
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 65
HBsAg loss is enough to discontinue long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients in real practice 65
Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naive patients with chronic hepatitis B followed for 3 years in a multicenter European study 64
Adefovir resistance patterns in patients with lamivudine resistant chronic hepatitis B 64
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 64
Epatite acuta C a risoluzione spontanea: evoluzione a lungo termine 64
Malattie causate da Elminti 64
Long-term follow up of patients with acute hepatitis C and spontaneous resolution 63
ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 62
Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment 62
Mutations selected during lamivudine therapy may predispose to adefovir resistance 62
Diagnostic value of alpha-fetoprotein for early hepatocellular carcinoma diagnosis in cirrhotic HBV patient successfully treated with nucleos(t)ide analogues - a case report 62
Epatite B e Immigrazione 61
Dalla terapia di combinazione Lamivudina+Adefovir alla monoterapia con Tenofovir in pazienti con Epatite Cronica B, HBeAg-negativa: risultati di efficacia e sicurezza 61
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 61
Risk of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues and long-term virological suppression 60
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin. 19th International Symposium on Hepatitis C Virus and Related Viruses 59
Early hepatic flares during ETV treatment are rare and do not require treatment adaptation in chronic hepatitis B without cirrhosis 59
No beneficial of long-term analogue treatment on the clinical outcome of patients with chronic hepatitis Delta and advanced liver disease. A case-control study. 59
Effectiveness of entecavir in field practice: interim analysis of the Italian MASTER-ENTAS cohort study of patients with chronic hepatitis B 58
Impact of adding raltegravir to antiretroviral regimens in patients with blood viral suppression but persistent seminal viral shedding 58
Long-Term HDV-RNA Suppression – HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy 57
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 56
HBV and immigrants: a SIMIT multicenter cross-sectional study 56
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 56
Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy 56
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 56
Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months 55
Maintained viral suppression and excellent safety profile of Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B: a 4-year field practice, multicenter study 55
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 54
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 54
Risposta a lungo termine alla monoterapia con lamivudina in pazienti con epatite cronica B, HBeAg negativa: è opportuno cambiare? 54
Epatite acuta C in pazienti in trattamento emodialitico periodico. 54
Interim analysis of the Italian Master-Entas cohort study: entecavir can improve liver function in patients with chronic hepatitis B and liver cirrhosis 53
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-Interferon α-2b versus a 12-week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with Acute Hepatitis C 53
Efficacia e tollerabilità a lungo termine della monoterapia con entecavir in pazienti con Epatite Cronica B 53
HBV e migranti: risultati di uno studio multicentrico SIMIT 53
HBSAG LOSS IS ENOUGH TO DISCONTINUE LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN REAL PRACTICE? 53
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 53
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 53
Studio multicentrico, randomizzato per valutare l’efficacia e la sicurezza di un ciclo di monoterapia con Peg-Interferone alfa-2b della durata di 24 settimane verso un trattamento di 12 settimane di Peg-interferone alfa-2b in monoterapia o in associazione alla ribavirina in pazienti con epatite acuta C 53
Entecavir in “real-life”: risultati dello studio VIRGIL 52
Terapia a lungo termine con Lamivudina in pazienti con epatite cronica B anti-HBe positiva: quando sospendere? 52
ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS 52
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. 52
Lack of association between IL28B variants and HBsAg clearance after interferon treatment 51
Effectiveness of entecavir for nuc-naive HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 51
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 50
Reply. 50
ENTECAVIR EFFECTIVENESS IN DAILY CLINICAL PRACTICE, INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 50
Epatiti virali croniche e gravidanza 50
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome 50
Effectiveness and safety of therapy simplification from Lamivudine + Adefovir to Tenofovir monotherapy in virologically suppressed HBeAg-negative chronic hepatitis B patients 49
Prediction of hepatocellular carcinoma in entecavir treated patients: results from 744 chronic hepatitis B patients in European Multicenter Study (VIRGIL) 47
Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 302 NUC-naïve patients with chronic hepatitis B 47
La genetica dei virus epatitici: implicazioni cliniche e terapeutiche 47
Efficacia e sicurezza della terapia a lungo termine con Entecavir (ETV) o Tenofovir (TDF) in pazienti con cirrosi epatica HBV correlata 45
Il caso clinico: monoterapia o terapia di combinazione?. 44
Totale 6.527
Categoria #
all - tutte 24.614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.614


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019192 0 0 0 0 0 0 0 7 7 14 16 148
2019/20201.532 353 140 81 18 201 205 212 18 130 26 133 15
2020/2021917 127 2 105 8 109 9 121 21 119 118 28 150
2021/2022554 74 8 7 9 73 32 15 54 66 68 16 132
2022/20232.031 237 91 58 76 53 138 2 127 1.184 26 22 17
2023/2024172 37 13 8 16 21 43 26 8 0 0 0 0
Totale 6.656